14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GRML vs IMNN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Imunon, Inc. (IMNN) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GRML carries a Unified Composite Score of 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin), whereas IMNN carries 32.2/100 (SELL) at $0.56 (16.8x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. IMNN 32.2/100 SELL), IMNN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile IMNN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs IMNN. Trailing 12-month operating profitability (GRML N/A vs IMNN 0.0%) and valuation multiples (GRML N/M vs IMNN 16.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GRML vs IMNN Key Questions & Quantitative Answers
As of Nov 16, 2026, Imunon, Inc. (IMNN) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GRML carries a Unified Composite Score of 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin), whereas IMNN carries 32.2/100 (SELL) at $0.56 (16.8x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. IMNN 32.2/100 SELL), IMNN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile IMNN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMNN leads the Growth & Scale pillar: GRML posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IMNN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $125,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GRML generates N/A in USD-normalized revenue versus $125,000 for IMNN. In operating R&D and SG&A reinvestment, GRML deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMNN.
IMNN screens cheaper on headline valuation multiples. GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IMNN trades at 16.8x Forward P/E, 16.8x Trailing P/E, 5.03x PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRML (N/A ROE) versus IMNN (-429.7% ROE) capital efficiency.
In options market volatility and institutional positioning, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk). By comparison, IMNN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 145% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.